AstraZeneca shares plunge over 9% as heart disease drug trial misses key goal

Traders Union
All News
Financial News
AstraZeneca slides 9.02% today

Highlights

AstraZeneca's lead heart disease therapy failed its primary endpoints in a late-stage trial, pressuring near-term sentiment.
Management announced multiple multi-billion-dollar partnerships and licensing deals in respiratory and oncology to bolster pipeline diversification.
Shares gapped down over 9%, trade below key technical levels, and are forecast to consolidate between GBX11,074 and GBX13,257 amid mixed momentum signals.

New licensing deals offset negative trial sentiment amid portfolio shifts

AstraZeneca reported that its late-stage trial for a heart disease treatment did not achieve its main objectives. Additional developments included the announcement of new licensing deals, such as a $2.1 billion agreement with Sino Biopharmaceutical for a potential COPD drug competitor, and the granting of ordinary shares to an officer as part of a share incentive plan. The company also remained active with partnerships for its oncology portfolio through deals with Helix and Daiichi Sankyo. Multiple licensing and research alliances were disclosed over the period.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s sharp decline as a consequence of its failed heart disease trial, reinforcing bearish sentiment. He highlights that price action is weak, trading below all moving averages and struggling to reclaim any bullish momentum. Kharitonov is skeptical of the positive signals from some technical indicators due to the overwhelming seller pressure and significant opening gap. The flurry of new deals may provide some mid-term narrative support but fails to offset immediate weakness. "The outlook remains fragile until AstraZeneca regains key technical levels and proves that recent licensing activity can reverse negative sentiment," he warns.

Viktoras Karapetjanc, expert at Traders Union, finds opportunity in AstraZeneca’s volatility despite recent trial disappointment. He points out that the company’s strategic partnerships and licensing deals show strong commitment to innovation. Karapetjanc remains confident that the increased activity in the COPD and oncology spaces could underpin future growth. Even with the technical setback, he sees room for a constructive rebound. "I believe AstraZeneca is well-positioned for recovery, and its bullish structure could quickly re-emerge as positive catalysts develop," he states.

Parshwa Turakhiya, analyst, notes AstraZeneca’s sharp move has driven heightened short-term trading activity. He observes mixed momentum signals, with buyers stepping in after the initial drop but sellers still influencing intraday sentiment. Turakhiya believes sideways consolidation is likely near current levels as the market digests both the clinical news and recent partnerships. "Traders should watch the boundaries at GBX13,107 and GBX12,388 closely for breakout setups," he says.

Mixed momentum amid all-timeframe seller dominance and support tests

AstraZeneca is trading below all key moving averages, with the latest price at GBX12,956 under the MA-20 (GBX13,821), MA-50 (GBX13,731), and MA-200 (GBX13,768), signaling seller pressure across short-, medium-, and long-term trends. The Ichimoku Kijun at GBX13,179 sets resistance, while the near-term ceiling at GBX13,107 and near-term floor at GBX12,388 highlight immediate levels to monitor. Momentum indicators are mixed: while MACD, RSI, and CCI flash buy signals, the ADX shows a sell and Stochastic RSI points to active sellers. Bull/Bear Power is positive, indicating buyer dominance, but the indicator also warns of overbought conditions. Today’s session saw a sharp drop of GBX1,284 (9.02%) with an opening downside gap of about GBX1,852 (13.01%), and price now sits close to the intraday high after recovering from early pressure, diverging from some momentum signals.

Previously it was reported that AstraZeneca’s failed heart disease trial led to heightened selling pressure and lingering concerns about its development pipeline. The current setup, with both persistent downside momentum and conflicting technical signals, suggests traders should closely monitor GBX12,388 as a make-or-break level for near-term direction.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.